Compare HCSG & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCSG | TOVX |
|---|---|---|
| Founded | 1976 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Assisted Living Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 6.4M |
| IPO Year | 1994 | 2012 |
| Metric | HCSG | TOVX |
|---|---|---|
| Price | $19.60 | $0.21 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 1 |
| Target Price | ★ $19.83 | N/A |
| AVG Volume (30 Days) | 612.7K | ★ 2.6M |
| Earning Date | 04-22-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 52.83 | ★ 89.07 |
| EPS | ★ 0.81 | N/A |
| Revenue | ★ $1,837,173,000.00 | N/A |
| Revenue This Year | $7.39 | N/A |
| Revenue Next Year | $5.22 | N/A |
| P/E Ratio | $23.40 | ★ N/A |
| Revenue Growth | ★ 7.08 | N/A |
| 52 Week Low | $9.13 | $0.16 |
| 52 Week High | $22.98 | $1.50 |
| Indicator | HCSG | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 45.06 | 62.42 |
| Support Level | $18.28 | $0.17 |
| Resistance Level | $19.77 | $0.22 |
| Average True Range (ATR) | 0.67 | 0.01 |
| MACD | -0.20 | 0.00 |
| Stochastic Oscillator | 27.89 | 42.55 |
Healthcare Services Group Inc is a provider of housekeeping and facility management services to the healthcare industry. The company manages and evaluates its operations in two reportable segments: Environmental Services segment includes housekeeping, management of clients' housekeeping departments, cleaning, disinfecting and sanitizing, laundry, bed linen, and uniform services, linen and other services; and Dietary Segment includes dietary department services, food purchasing, meal preparation, and providing dietitian consulting services. Its clients are nursing homes, retirement complexes, rehabilitation centers, and hospitals in the United States of America. The Environmental Services segment derives maximum revenue.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.